You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Metastatic melanoma - a review of current and future treatment options.
|
|---|---|
| Published in |
Acta Dermato-Venereologica, January 2015
|
| DOI | 10.2340/00015555-2035 |
| Pubmed ID | |
| Authors |
Emanual Maverakis, Lynn A Cornelius, Glen M Bowen, Tiffany Phan, Falin B Patel, Sarah Fitzmaurice, Young He, Barbara Burrall, Christopher Duong, April M Kloxin, Hawa Sultani, Reason Wilken, Steve R Martinez, Forum Patel |
| Abstract |
Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette-Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive T cell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment. |
X Demographics
The data shown below were collected from the profiles of 48 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 11 | 23% |
| Spain | 2 | 4% |
| Brazil | 1 | 2% |
| Iraq | 1 | 2% |
| Australia | 1 | 2% |
| Mexico | 1 | 2% |
| Venezuela, Bolivarian Republic of | 1 | 2% |
| Colombia | 1 | 2% |
| Poland | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 24 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 36 | 75% |
| Scientists | 7 | 15% |
| Science communicators (journalists, bloggers, editors) | 3 | 6% |
| Practitioners (doctors, other healthcare professionals) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 326 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | <1% |
| Pakistan | 1 | <1% |
| Unknown | 324 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 59 | 18% |
| Student > Ph. D. Student | 54 | 17% |
| Student > Bachelor | 51 | 16% |
| Researcher | 31 | 10% |
| Student > Doctoral Student | 19 | 6% |
| Other | 45 | 14% |
| Unknown | 67 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 68 | 21% |
| Medicine and Dentistry | 63 | 19% |
| Agricultural and Biological Sciences | 51 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 6% |
| Immunology and Microbiology | 14 | 4% |
| Other | 37 | 11% |
| Unknown | 73 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 51. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2023.
All research outputs
#846,954
of 26,017,215 outputs
Outputs from Acta Dermato-Venereologica
#21
of 2,157 outputs
Outputs of similar age
#10,666
of 365,327 outputs
Outputs of similar age from Acta Dermato-Venereologica
#2
of 93 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,157 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,327 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.